FilingReader Intelligence

Hengrui advances oncology and ophthalmology pipelines with new approvals

July 3, 2025 at 05:05 PM UTCBy FilingReader AI

Jiangsu Hengrui Medicine announced significant progress in its oncology and ophthalmology pipelines. Its subsidiary, Suzhou Shengdiya Biomedical, received approval from the National Medical Products Administration (NMPA) to begin clinical trials for SHR-4506 injection, a Class 1 therapeutic biologic intended for the treatment of advanced malignancies. Preclinical studies have demonstrated promising anti-tumor activity. As of now, the cumulative R&D investment in SHR-4506 related projects has reached CNY 19.92 million.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

SSE:600276Shanghai Stock Exchange
Shanghai Blue Chip

News Alerts

Get instant email alerts when Jiangsu Hengrui Medicine publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →